Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them

1. A method of treating pain in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof an amount of a compound selected from the group consisting of a compound of the formula

wherein A is selected from the group consisting of

and

R 1 and R 2 are individually selected from the group consisting of hydrogen, halogen, —OH, alkyl of 1 to 6 carbon atoms and alkoxy of 1 to 6 carbon atoms, R 3 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and —COR 4 , R 4 is alkyl of 1 to 6 carbon atoms, B is selected from the group consisting of alkyl of 1 to 6 carbon atoms and carbocyclic aryl and heterocyclic aryl of 5 to 6 ring members containing in the ring 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur with the aryl unsubstituted or substituted with at least one member of the group consisting of alkyl, alkenyl and alkoxy of up to 6 carbon atoms, X is selected from the group consisting of a single bond, —Z 1 , —Z 1 CO—, —CH═, —CH═CH—CO—, —Z 1 —NR 3 —CO—Z′ 1 —, —CONR 3 —Z′ 1 , —Z 1 —NR 3 —CS— and —Z 1 —NR 3 —SO 3 —, Het is a heterocycle selected from the group consisting of oxetane, pyrrole, pyrrolidine, furan, tetrahydrofuran, thiophene, tetrahydrothiophene, sulpholane, imidazole, imidazoline, dihydroimidazole-2-one, dihydroimidazole-2-thione, oxazole, isoxazole, oxazoline, isoxazoline, oxazolidine, oxazolidinone, thiazole, thiazoline, thiazolidine, thiazolidinone, hydantoine, 1,2,4-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,1-dioxyde-1,2,5-thiadiazolidine, 1,2,4-triazole-3-one, tetrazole, tetrahydropyridine, piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethyl-piperazine and 4-aminopiperidine, Y is selected from the group consisting of Z 2 —Q—, —Z 2 CO—, —Z 2 —NH—CO—, —Z 2 —CH 2 —NR 3 —CO—, —NR 3 —Z 2 —Q—, —NR 3 —CO—Z 2 —Q—, —NR 3 —NH—CO—Z 2 —, —NH—NH—Z 2 —, —NR 3 —O—Z 2 —, —NR 3 —SO 2 —NR 3 —Z 2 —, —O—Z 2 —Q—, —O—CO—Z 2 —Q— and —S—Z 2 —Q—, Q is selected from the group consisting of —O—Z 3 , —R 3 —N—Z 3 and —S—Z 3 , Z 1 , Z′ 1 , Z′ 2 and Z 3 are individually selected from the group consisting of a single bond and alkylene of 1 to 6 carbon atoms, R 6 is hydrogen or —OH and its non-toxic, pharmaceutically acceptable salts sufficient to treat pain.

2. The method of claim 1 wherein A is

wherein R 1 and R 2 are individually branched alkyl of 3 to 6 carbon atoms and R 3 and R4 are defined as in claim 1 .

3. The method of claim 1 wherein B is

wherein R 3 is defined as in claim 1 and its pharmaceutically acceptable salts.

4. The method of claim 1 selected from the group consisting of

N-[4-1H-imidazol-1-phenyl]-2-thiophenecarboximidamide;

N-[4-(3-thiazolidinylmethyl)phenyl]-2-thiophenecarboximidamide;

N-[4-(1,2,3,6-tetrahydropyridin-1-yl)phenyl]-2-thiophenecarboximidamide;

N-[4-(1H-imidazol-1-yl methyl]-2-thiophenecarboximidamide;

N-[4-{2-(3-thiazolidinyl)ethyl}phenyl-[-2-thiophenecarboximidamide;

N-{4-[2-1H-imidazol-1-yl)ethyl]phenyl}-2-thiophenecarboximidamide;

N-{4-[2-(1,2,3,6-tetrahydropropyridin-1-yl)ethyl]phenyl}-2-thiophenecarboximidamide;

N-[4-thiazolidinylcarbonylmethyl)phenyl]-2-thiophenecarboximidamide;

N-(4-{[2-thiazolidinyl]carbonylaminomethyl}phenyl)-2-thiophenecarboximidamide;

N-(3,5 di-t-butyl-4-hydroxyphenyl)-5-[4-{imino(2-thienyl)-methylamino}phenyl]-2-furancarboxamide;

3-(3,5-di-t-butyl-4-hydroxyphenyl)-1-[4- {imino(2-thienyl)-methylamino}phenyl]2,5-imidazolidinedione;

2-(3,5-di-t-butyl-4-hydroxyphenyl)-3-[4- {imino(2-thienyl)-methylamino}phenyl]4 -thiazolidinone;

5-[(3,5-di-t-butyl-4-hydroxyphenyl)methylene]-1-methyl-3-[4-{imino(2-thienyl)methylamino)phenyl]-2,4-imidazolidinedione;

2-(S)-4-(S)-N-[4-hydroxy-3,5-bis(1,1-dimethylethyl)-phenyl]-4-{4-[(imino(2-thienyl)methyl)amino]phenoxy}-prolinamide;

5,6-dihydro-N-{4-[(imino(2-thienyl)methyl)amino]phenyl}-1-(2H)-pyridine carboxamide;

N-[4-hydroxy-3,5-bis-(1,1-dimethylethyl)phenyl]-2-(RS)- {4-(imino(2-thienyl) methyl)amino]phenyl)}-4-(R)-thiazolidine carboxamide;

N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-{4-[(imino(2-thienyl)-methyl)amino]phenyl}-4-thiazolecarboxamide;

N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-(S)-{4[-(imino(2-thienyl) methyl)amino]phenoxy}-pyrrolidine-2-(R)-carboxamide;

methyl-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2-H-[1]-benzopyran-2-yl)carbonyl]-4-(S)-{4-[(imino(2-thienyl)amino]-phenoxy}-pyrrolidine-2-(S)-carboxylate;

1-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-3-(S)-{4-[(imino(2-thienyl)methyl)amino]phenoxy}-pyrrolidine;

3-{[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-]1[-benzopyran-2-yl) carbonyl]amino}-1-{4-[(imino(2-thienyl)methyl)amino]phenyl]pyrrolidine;

4-[3,5-bis (1,1-dimethylethyl)-4-hydroxyphenyl]-N-{4-(imino(2-thienyl) methyl)amino]benzoyl]}-N-methyl-1H-imidazole-2-methanamine;

N-[3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-{4-[(imino(2-thienyl) methyl)amino]phenyl}-[1H]-pyrrole-2-carboxamide;

1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-{[4-[(imino(2-thienyl) methyl]amino]phenyl]carbonyl}-2-imidazolidinone;

3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4,5-dihydro-N-{4-[imino(2-thienyl)methyl)amino]phenyl}-5-isoxazoleacetamide;

4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-{4-[(imino(2-thienyl) methyl)amino]phenyl}-N-methyl-2-thiazolemethanamine;

4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-{4-[(imino(2-thienyl) methyl)amino]phenyl}-N-methyl-1H-imidazole-2-methanamine;

3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4,5-dihydro-5-{2-{4-[(imino( 2-thienyl)methyl)amino[phenoxy}ethyl}isoxazole;

1-{[3,5-bis( 1,1-dimethylethyl)-4-hydroxyphenyl]amino}-carbonyl}-3-{4-[imino(2-thienyl)methyl)amino]phenoxy}azetidine;

1-(2-hydroxy-5-methoxybenzoyl)-3-{4-[(imino(2-thienyl)methyl)amino]phenoxy}azetidine;

1-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-4-[4-[(imino(2-thienyl)methyl)amino]phenoxy}-piperidine;

1-[3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-3-{4-[(imino(2-thienyl)methyl)amino]-phenoxy}azetidine; or its non-toxic pharmaceutically acceptable salts.

5. The method of claim 1 of the formula

wherein A is selected from the group consisting of hydrogen,

and

R 1 , R 2 , R 3 , R 4, Het and B are defined as in claim 1 , X is selected from the group consisting of —CO—NR 3 —X′, —NH—CO—X′, —CH═, —CO— and a bond, X′ is —(CH 2 )m—, m is an integer from 0 to 6, Y is selected from the group consisting of —Y′—, —CO—NH—Y′—, —Y′—NH——CO—, —COY′—, —Y′—CO—, —NR 3 —y′—, —y′—NR 3 —, —Y′—CH 2 —NR 3 —CO—, —OY′—, —Y′—O—, —S—Y′—, —Y′—S—, —Y′—O—Y′—, —Y′—NR 3 —Y′— and a bond, Y′ is —(CH 2 ) n− , n is an integer from 0 to 6 with the proviso that when A is hydrogen, Het is not piperidino or pyrrolidino or morpholino and its pharmaceutically acceptable salts.

6. The method of claim 1 wherein the compound is (S)N-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)-1-piperazinyl]-phenyl}-2-thiophenecarboximidamide or a non-toxic, pharmaceutically acceptable salt thereof.